For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Lynparza is already the most widely-used PARP inhibitor, and the new results could help to extend its lead over rivals in the class like GSK's Zejula (niraparib), Pfizer's Talzenna (talazoparib ...

Despite improvements in neuroblastoma treatment, survival figures lag behind those of many other childhood malignancies. New treatments, and better use of existing treatments, are essential to reduce ...

New Diagnostics, AI Breakthroughs, and Next-Gen Therapies Are Transforming the Oncology Market. The oncology sector is experiencing <stron ...